Peptide Nucleic Acids (PNAs) are synthetic DNA mimics known for their exceptional binding strength and sequence specificity. While PNAs hold great promise in gene regulation and molecular diagnostics, their clinical application can be limited by poor water solubility and suboptimal pharmacokinetics. Our PNA PEGylation services are designed to overcome these limitations through precise, site-specific PEG conjugation. By attaching polyethylene glycol (PEG) chains to PNAs, we enhance their biostability, solubility, cellular uptake, and in vivo circulation time—making them more effective for use in drug delivery systems, nanomedicine platforms, and diagnostic assays.
Peptide Nucleic Acid (PNA) is a synthetic analogue of DNA/RNA characterized by a peptide-like backbone structure, allowing it to bind to nucleic acids with high affinity and specificity. Polyethylene glycol (PEG) is a biocompatible and hydrophilic polymer often used to modify biomolecules. PEGylation is the process of covalently attaching PEG chains to molecules, including drugs, peptides, or proteins. PEGylation of PNAs refers to the chemical modification of peptide nucleic acids by covalently attaching PEG polymers to their backbone. PNAs are synthetic analogs of DNA or RNA with a unique peptide-like backbone, allowing for strong and selective hybridization with target nucleic acid sequences. PEG (polyethylene glycol), a highly hydrophilic and biocompatible polymer, is widely used to improve the pharmacological properties of therapeutic molecules.
PEGylated PNA is created by chemically modifying PNA to introduce reactive groups (e.g., amines or thiols), which are then conjugated to PEG via esterification or amide bond formation. PEGylated PNA combines the high-affinity nucleic acid binding of peptide nucleic acid (PNA) with the stabilizing effects of polyethylene glycol (PEG). The PEGylation enhances PNA's solubility, reduces nonspecific adsorption, and prolongs circulation time, improving its efficacy in gene regulation.
PEGylation significantly enhances the therapeutic potential of peptide nucleic acid (PNA) through multiple key benefits:
The covalent attachment of polyethylene glycol (PEG) shields PNA from enzymatic degradation and improves its resistance to biological clearance, extending its shelf life and in vivo durability.
PEGylation increases PNA's hydrophilicity, preventing aggregation and ensuring better dispersion in aqueous solutions, facilitating easier formulation and administration.
The PEG corona reduces renal filtration and minimizes nonspecific interactions, significantly extending PNA's plasma half-life for sustained therapeutic effects.
PEG coating masks PNA from immune recognition, lowering the risk of adverse immune reactions and improving biocompatibility.
PEGylated PNA can be further functionalized with ligands (e.g., antibodies, peptides) for tissue-specific delivery, enhancing precision in gene silencing or antisense therapy.
Collectively, these advantages make PEGylated PNA a versatile tool for therapeutics, diagnostics, and nanotechnology.
PNA Oligonucleotide Synthesis
High-purity custom sequences (5–30mer)
Sequence design and modification support
PEG Type Selection
Linear PEGs (MW 500–20kDa)
Branched PEGs (2-arm, 4-arm)
Functional PEGs (NHS, Maleimide, Azide, Biotin, Fluorophore)
Terminal and Internal PEGylation
N-terminus, C-terminus, or internal lysine/cysteine residues
Chemistry Options
NHS ester – amine coupling
Maleimide – thiol conjugation
Click chemistry (azide–alkyne cycloaddition)
Multifunctional PEG Scaffolds
PNA–PEG–Drug, PNA–PEG–Antibody, PNA–PEG–Nanoparticle conjugates
Purification Techniques
Reverse-phase HPLC
Size-exclusion chromatography (SEC)
Analytical Characterization
Mass spectrometry (LC-MS or MALDI-TOF)
UV/Vis spectrophotometry
Degree of PEGylation confirmation
NMR analysis (upon request)
Cell-Penetrating Enhancements
CPP addition for intracellular delivery
a Bioconjugation Capabilities
Antibody or aptamer targeting
siRNA, miRNA, or oligo hybrid design
Nanocarrier Integration
Liposome or gold nanoparticle PEGylated PNA complexes
We offer flexible PEGylation strategies tailored to your sequence, application, and functional group needs.
All products undergo rigorous HPLC purification and LC-MS analysis to ensure batch-to-batch consistency and high purity.
From μmol-scale discovery batches to multi-mg preclinical lots—we adapt to your stage of development.
PEGylated PNAs demonstrate improved resistance to enzymatic degradation and increased plasma half-life.
Access to linear, branched, heterobifunctional, and multi-arm PEG reagents for full application flexibility.
Complete QC reports, storage recommendations, and technical support provided throughout the project.
PEGylated PNA holds significant promise across multiple biomedical fields. These versatile applications highlight PEGylated PNA's potential in advancing precision medicine and biotechnology.
PNA PEGylation serves as a targeted carrier, enhancing therapeutic precision while minimizing off-target effects.
PEGylation improves PNA's cellular uptake and stability, enabling efficient gene modulation.
PEGylated PNA enables sensitive detection of genetic mutations and molecular imaging.
Its incorporation into biomaterials enhances biocompatibility and biodegradability for tissue engineering and biosensors.
PEGylation improves the solubility, stability, and circulation time of PNA molecules. It reduces renal clearance, minimizes immunogenicity, and increases bioavailability—especially important in in vivo delivery and therapeutic applications.
Yes. We offer a wide range of linear (e.g., 1kDa–20kDa) and branched PEGs, including functionalized versions like mPEG-NHS, mPEG-MAL, biotin-PEG, or fluorescent PEGs. Our team will help recommend the best PEG type for your application.
Absolutely. We support multi-functional PEG scaffolds that allow dual conjugation—for example, PNA–PEG–fluorophore, PNA–PEG–antibody, or PNA–PEG–nanoparticle constructs. Just let us know your design goals.
References
Global Supplier of High-Quality RNA / DNA Products & Services.
